Amling C L, Lerner S E, Martin S K, Slezak J M, Blute M L, Zincke H
Department of Urology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
J Urol. 1999 Mar;161(3):857-62; discussion 862-3.
We assessed clinical and pathological variables for the ability to predict improved outcome following salvage prostatectomy for radiation refractory prostate cancer. We identify factors that might assist in selection of candidates for this procedure.
Between 1966 and 1996, 108 patients (mean age 64.7 years) underwent salvage radical retropubic prostatectomy for radiation refractory prostate cancer. Preoperative serum prostate specific antigen (PSA), available in 70 patients treated since 1987, was less than 4 in 19, 4 to 10 in 31 and greater than 10 ng./ml. in 20. Serum PSA before radiotherapy was available in 37 patients. Serum PSA before radiotherapy and salvage surgery, tumor grade, deoxyribonucleic acid (DNA) ploidy and margin status were analyzed for the ability to predict cancer specific and progression-free survival (local, systemic and PSA 0.2 ng./ml. or greater). Complication rates were compared between early (before 1990) and late (1990 to 1996) salvage prostatectomy groups.
Overall cancer specific and progression-free survival at 10 years was 70 and 44%, respectively. The pathological stage was pT2N0 in 39%, pT3-4N0 in 42% and pTxN+ in 19% of cases. DNA ploidy was predominately nondiploid, that is diploid in 25%, tetraploid in 64% and aneuploid in 11% of tumors. Although preoperative serum PSA was not predictive of pathological stage, patients with preoperative PSA less than 10 ng./ml. had better progression-free survival than those with higher levels (p = 0.05). DNA ploidy was the strongest predictor of cancer specific (p = 0.002) and progression-free (p = 0.002) survival. Controlling for grade and PSA using the Cox proportional hazards model, DNA ploidy remained a significant predictor of prostate cancer death (p <0.001) and disease progression (p <0.001). Complication rates improved somewhat in more recently treated patients but incontinence and bladder neck contracture rates remained significant.
DNA ploidy and preoperative serum PSA appear to be the most important predictors of outcome following salvage prostatectomy for radiation refractory prostate cancer. Preoperative consideration of these factors may be helpful in selecting candidates for this procedure.
我们评估了临床和病理变量预测放射性难治性前列腺癌挽救性前列腺切除术后改善结局的能力。我们确定了可能有助于选择该手术候选人的因素。
1966年至1996年间,108例患者(平均年龄64.7岁)接受了放射性难治性前列腺癌的挽救性耻骨后根治性前列腺切除术。自1987年以来接受治疗的70例患者中有术前血清前列腺特异性抗原(PSA)数据,其中19例患者的PSA小于4,31例患者的PSA在4至10之间,20例患者的PSA大于10 ng/ml。37例患者有放疗前血清PSA数据。分析放疗前和挽救性手术前的血清PSA、肿瘤分级、脱氧核糖核酸(DNA)倍体和切缘状态预测癌症特异性生存和无进展生存(局部、全身以及PSA为0.2 ng/ml或更高)的能力。比较早期(1990年之前)和晚期(1990年至1996年)挽救性前列腺切除术组之间的并发症发生率。
10年时总体癌症特异性生存率和无进展生存率分别为70%和44%。病理分期为pT2N0的病例占39%,pT3 - 4N0的病例占42%,pTxN+的病例占19%。DNA倍体主要为非二倍体,即25%的肿瘤为二倍体,64%为四倍体,11%为非整倍体。虽然术前血清PSA不能预测病理分期,但术前PSA小于10 ng/ml的患者无进展生存率高于PSA水平较高的患者(p = 0.05)。DNA倍体是癌症特异性生存(p = 0.002)和无进展生存(p = 0.002)的最强预测因素。使用Cox比例风险模型控制分级和PSA后,DNA倍体仍然是前列腺癌死亡(p <0.001)和疾病进展(p <0.001)的显著预测因素。在近期接受治疗的患者中并发症发生率有所改善,但尿失禁和膀胱颈挛缩发生率仍然较高。
DNA倍体和术前血清PSA似乎是放射性难治性前列腺癌挽救性前列腺切除术后结局的最重要预测因素。术前考虑这些因素可能有助于选择该手术的候选人。